🚀 VC round data is live in beta, check it out!
Nanologica Overview
About Nanologica
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
Founded
2004
HQ
Employees
15
Website
Sectors
Financials (FY)
EV
$11M
Nanologica Financials
Nanologica reported last fiscal year revenue of $2M and negative EBITDA of ($4M).
In the same fiscal year, Nanologica generated $469K in gross profit, ($4M) in EBITDA losses, and had net loss of ($6M).
Revenue (LTM)
Nanologica P&L
In the most recent fiscal year, Nanologica reported revenue of $2M and EBITDA of ($4M).
Nanologica expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $469K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 20% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (162%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (233%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (243%) | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nanologica Stock Performance
Nanologica has current market cap of $9M, and enterprise value of $11M.
Market Cap Evolution
Nanologica's stock price is $0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11M | $9M | 0.3% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNanologica Valuation Multiples
Nanologica trades at 4.6x EV/Revenue multiple, and (2.9x) EV/EBITDA.
EV / Revenue (LTM)
Nanologica Financial Valuation Multiples
As of April 19, 2026, Nanologica has market cap of $9M and EV of $11M.
Equity research analysts estimate Nanologica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanologica has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 22.8x | XXX | XXX | XXX |
| P/E | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nanologica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nanologica Margins & Growth Rates
Nanologica's revenue in the last fiscal year grew by 45%.
Nanologica's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Nanologica Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 45% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (162%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (24%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 253% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nanologica Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nanologica | XXX | XXX | XXX | XXX | XXX | XXX |
| AcouSort | XXX | XXX | XXX | XXX | XXX | XXX |
| GenIP | XXX | XXX | XXX | XXX | XXX | XXX |
| Fluicell | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Harvard Apparatus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanologica M&A Activity
Nanologica acquired XXX companies to date.
Last acquisition by Nanologica was on XXXXXXXX, XXXXX. Nanologica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nanologica
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNanologica Investment Activity
Nanologica invested in XXX companies to date.
Nanologica made its latest investment on XXXXXXXX, XXXXX. Nanologica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nanologica
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nanologica
| When was Nanologica founded? | Nanologica was founded in 2004. |
| Where is Nanologica headquartered? | Nanologica is headquartered in Sweden. |
| How many employees does Nanologica have? | As of today, Nanologica has over 15 employees. |
| Who is the CEO of Nanologica? | Nanologica's CEO is Andreas Bhagwani. |
| Is Nanologica publicly listed? | Yes, Nanologica is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Nanologica? | Nanologica trades under NICA ticker. |
| When did Nanologica go public? | Nanologica went public in 2015. |
| Who are competitors of Nanologica? | Nanologica main competitors are AcouSort, GenIP, Fluicell, AnteoTech. |
| What is the current market cap of Nanologica? | Nanologica's current market cap is $9M. |
| What is the current revenue of Nanologica? | Nanologica's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Nanologica? | Current revenue multiple of Nanologica is 4.6x. |
| Is Nanologica profitable? | No, Nanologica is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.